Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AC Platelet aggregation inhibitors excl. heparin
B01AC21 Treprostinil
D08628 Treprostinil monosodium salt
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG00161 Treprostinil
D08628 Treprostinil monosodium salt
Hormonal agent
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
DG00161 Treprostinil
D08628 Treprostinil monosodium salt
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00161 Treprostinil
D08628 Treprostinil monosodium salt
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostacyclin
PTGIR
D08628 Treprostinil monosodium salt
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08628
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08628
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08628
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01712 Antiplatelet agent
DG00161 Treprostinil
Hormonal agent
DG01961 Prostaglandin derivative
DG01810 Prostacycline derivative
DG00161 Treprostinil
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG00161 Treprostinil